> str(dataset)
List of 5
 $ drugs     :List of 28
  ..$ general_information    : tibble [17,430 × 15] (S3: tbl_df/tbl/data.frame)
  .. ..$ drugbank_id        : chr [1:17430] "DB00001" "DB00002" "DB00003" "DB00004" ...
  .. ..$ other_keys         : chr [1:17430] "BTD00024;BIOD00024" "BTD00071;BIOD00071" "BTD00001;BIOD00001" "BTD00084;BIOD00084" ...
  .. ..$ type               : chr [1:17430] "biotech" "biotech" "biotech" "biotech" ...
  .. ..$ created            : chr [1:17430] "2005-06-13" "2005-06-13" "2005-06-13" "2005-06-13" ...
  .. ..$ updated            : chr [1:17430] "2024-11-03" "2025-01-02" "2024-12-14" "2025-01-02" ...
  .. ..$ name               : chr [1:17430] "Lepirudin" "Cetuximab" "Dornase alfa" "Denileukin diftitox" ...
  .. ..$ description        : chr [1:17430] "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin "| __truncated__ "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal "| __truncated__ "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in geneticall"| __truncated__ "Denileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed"| __truncated__ ...
  .. ..$ cas_number         : chr [1:17430] "138068-37-8" "205923-56-4" "143831-71-4" "173146-27-5" ...
  .. ..$ unii               : chr [1:17430] "Y43GF64R34" "PQX0D8J21J" "953A26OA1Y" "25E79B5CTM" ...
  .. ..$ average_mass       : chr [1:17430] NA NA NA NA ...
  .. ..$ monoisotopic_mass  : chr [1:17430] NA NA NA NA ...
  .. ..$ state              : chr [1:17430] "solid" "liquid" "liquid" "liquid" ...
  .. ..$ synthesis_reference: chr [1:17430] "Recombinant hirudin expressed by using yeast secretary (China Patent No. CN1371994A, 2001). China National Inte"| __truncated__ "" "" "" ...
  .. ..$ fda_label          : chr [1:17430] NA "//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813" "//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221" NA ...
  .. ..$ msds               : chr [1:17430] NA "//s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933" "//s3-us-west-2.amazonaws.com/drugbank/msds/DB00003.pdf?1410714694" NA ...
  ..$ drug_classification    : tibble [11,154 × 9] (S3: tbl_df/tbl/data.frame)
  .. ..$ description        : chr [1:11154] "" "" "" "" ...
  .. ..$ direct_parent      : chr [1:11154] "Peptides" "Peptides" "Peptides" "Peptides" ...
  .. ..$ kingdom            : chr [1:11154] "Organic Compounds" "Organic Compounds" "Organic Compounds" "Organic Compounds" ...
  .. ..$ superclass         : chr [1:11154] "Organic Acids" "Organic Acids" "Organic Acids" "Organic Acids" ...
  .. ..$ class              : chr [1:11154] "Carboxylic Acids and Derivatives" "Carboxylic Acids and Derivatives" "Carboxylic Acids and Derivatives" "Carboxylic Acids and Derivatives" ...
  .. ..$ subclass           : chr [1:11154] "Amino Acids, Peptides, and Analogues" "Amino Acids, Peptides, and Analogues" "Amino Acids, Peptides, and Analogues" "Amino Acids, Peptides, and Analogues" ...
  .. ..$ alternative_parents: chr [1:11154] "" "" "" "" ...
  .. ..$ substituents       : chr [1:11154] "" "" "" "" ...
  .. ..$ drugbank_id        : chr [1:11154] "DB00001" "DB00002" "DB00003" "DB00004" ...
  ..$ synonyms               : tibble [39,982 × 4] (S3: tbl_df/tbl/data.frame)
  .. ..$ synonym    : chr [1:39982] "[Leu1, Thr2]-63-desulfohirudin" "Desulfatohirudin" "Hirudin variant-1" "Lepirudin" ...
  .. ..$ language   : chr [1:39982] "english" "english" "english" "english" ...
  .. ..$ coder      : chr [1:39982] "" "" "" "inn" ...
  .. ..$ drugbank_id: chr [1:39982] "DB00001" "DB00001" "DB00001" "DB00001" ...
  ..$ pharmacology           : tibble [17,430 × 12] (S3: tbl_df/tbl/data.frame)
  .. ..$ drugbank_id           : chr [1:17430] "DB00001" "DB00002" "DB00003" "DB00004" ...
  .. ..$ indication            : chr [1:17430] "Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstab"| __truncated__ "Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and"| __truncated__ "Used as adjunct therapy in the treatment of cystic fibrosis. " "Denileukin diftitox was previously indicated for the treatment of adult patients with persistent or recurrent c"| __truncated__ ...
  .. ..$ pharmacodynamics      : chr [1:17430] "Lepirudin is a recombinant hirudin that acts as a highly specific thrombin inhibitor. Its activity is measured "| __truncated__ "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor re"| __truncated__ "Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways."| __truncated__ "Denileukin diftitox is an anticancer drug with cytocidal actions on cancer cells.[L51254] Denileukin diftitox d"| __truncated__ ...
  .. ..$ mechanism_of_action   : chr [1:17430] "Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicat"| __truncated__ "The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kina"| __truncated__ "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of ext"| __truncated__ "Denileukin diftitox is a fusion protein composed of truncated diphtheria toxin (DT), which is a cytocidal moiet"| __truncated__ ...
  .. ..$ toxicity              : chr [1:17430] "The acute toxicity of intravenous lepirudin was evaluated in mice (0.1-1000 mg/kg), rats (1-1000 mg/kg), and mo"| __truncated__ "The intravenous LD<sub>50</sub> is > 300 mg/kg in mice and > 200 mg/kg in rats.[L31408] There is limited inform"| __truncated__ "Adverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Reported adver"| __truncated__ "There is limited information regarding the acute toxicity (LD<sub>50</sub>) and overdose of denileukin diftitox." ...
  .. ..$ metabolism            : chr [1:17430] "As a polypeptide, lepirudin is expected to be metabolized by the sequential cleavage of amino acids by kidney e"| __truncated__ "Like other monoclonal antibodies, cetuximab is expected to undergo lysosomal degradation by the reticuloendothe"| __truncated__ "While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids. " "Denileukin diftitox is expected to be metabolized into small peptides by catabolic pathways.[L51254]" ...
  .. ..$ absorption            : chr [1:17430] "Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and f"| __truncated__ "After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the"| __truncated__ "Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 1"| __truncated__ "Following a single dose of denileukin diftitox 9 mcg/kg via one-hour infusion in patients with CTCL, the geomet"| __truncated__ ...
  .. ..$ half_life             : chr [1:17430] "Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a termi"| __truncated__ "After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the"| __truncated__ "" "The arithmetic mean (CV%) denileukin diftitox terminal half-life is 112 minutes (31%) on the first day of the f"| __truncated__ ...
  .. ..$ protein_binding       : chr [1:17430] "In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]" "There is no information available." "" "" ...
  .. ..$ route_of_elimination  : chr [1:17430] "Lepirudin is mostly excreted through urine (48.3%). About 35% of lepirudin is excreted unchanged, while metabol"| __truncated__ "There is limited information available." "" "" ...
  .. ..$ volume_of_distribution: chr [1:17430] "The volume of distribution of lepirudin at steady state was 12.2 L in healthy young subjects (n=18, 18-60 years"| __truncated__ "The volume of the distribution is about 2-3 L/m<sup>2</sup> and is independent of dose.[L30448]" "In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentratio"| __truncated__ "The geometric mean (CV%) volume of distribution of denileukin diftitox is 5.0 L (43%) on the first day of the f"| __truncated__ ...
  .. ..$ clearance             : chr [1:17430] "The clearance of lepirudin is proportional to the glomerular filtration rate. On average, lepirudin clearance w"| __truncated__ "In patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, the estimated cleara"| __truncated__ "Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa fr"| __truncated__ "The geometric mean (CV%) clearance is 36.5 mL/min (73%) after the first dose of denileukin diftitox at the reco"| __truncated__ ...
  ..$ international_brands   : tibble [8,880 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ brand      : chr [1:8880] "Viscozyme" "Davictrel" "Tunex" "Angiox" ...
  .. ..$ company    : chr [1:8880] "Roche (Chile)" "" "" "" ...
  .. ..$ drugbank_id: chr [1:8880] "DB00003" "DB00005" "DB00005" "DB00006" ...
  ..$ mixtures               : tibble [152,644 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ name       : chr [1:152644] "Enbrel" "Viadur" "Leuprolide Acetate" "Lupron Depot" ...
  .. ..$ ingredients: chr [1:152644] "Etanercept" "Leuprolide + Lidocaine" "Leuprolide" "Leuprolide" ...
  .. ..$ drugbank_id: chr [1:152644] "DB00005" "DB00007" "DB00007" "DB00007" ...
  ..$ packagers              : tibble [20,499 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ name       : chr [1:20499] "Bayer Healthcare" "Berlex Labs" "Cardinal Health" "Catalent Pharma Solutions" ...
  .. ..$ url        : chr [1:20499] "http://www.bayerhealthcare.com" "http://www.berlex.com" "http://www.cardinal.com" "http://www.catalent.com" ...
  .. ..$ drugbank_id: chr [1:20499] "DB00001" "DB00001" "DB00002" "DB00002" ...
  ..$ manufacturers          : tibble [5,971 × 4] (S3: tbl_df/tbl/data.frame)
  .. ..$ manufacturer: chr [1:5971] "Bayer healthcare pharmaceuticals inc" "Genentech, Inc" "Amgen Inc. + Wyeth + Takeda" "The medicines co" ...
  .. ..$ generic     : chr [1:5971] "false" "false" "false" "false" ...
  .. ..$ url         : chr [1:5971] "" "" "" "" ...
  .. ..$ drugbank_id : chr [1:5971] "DB00001" "DB00003" "DB00005" "DB00006" ...
  ..$ prices                 : tibble [11,807 × 5] (S3: tbl_df/tbl/data.frame)
  .. ..$ description: chr [1:11807] "Refludan 50 mg vial" "Lufyllin 200 mg tablet" "Lufyllin-gg tablet" "Lufyllin-GG 200-200 mg tablet" ...
  .. ..$ currency   : chr [1:11807] "USD" "USD" "USD" "USD" ...
  .. ..$ cost       : chr [1:11807] "273.19" "3.21" "3.84" "3.99" ...
  .. ..$ unit       : chr [1:11807] "vial" "tablet" "tablet" "tablet" ...
  .. ..$ drugbank_id: chr [1:11807] "DB00001" "DB00003" "DB00003" "DB00003" ...
  ..$ categories             : tibble [101,512 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ category   : chr [1:101512] "Amino Acids, Peptides, and Proteins" "Anticoagulants" "Antithrombin Proteins" "Antithrombins" ...
  .. ..$ mesh_id    : chr [1:101512] "D000602" "D000925" "D058833" "D000991" ...
  .. ..$ drugbank_id: chr [1:101512] "DB00001" "DB00001" "DB00001" "DB00001" ...
  ..$ dosages                : tibble [99,874 × 4] (S3: tbl_df/tbl/data.frame)
  .. ..$ form       : chr [1:99874] "Injection, powder, for suspension" "Injection, solution, concentrate" "Injection, solution, concentrate" "Powder" ...
  .. ..$ route      : chr [1:99874] "Intravenous" "Intravenous" "Intravenous" "Intravenous" ...
  .. ..$ strength   : chr [1:99874] "5000000 mg" "20 mg" "50 mg" "" ...
  .. ..$ drugbank_id: chr [1:99874] "DB00001" "DB00001" "DB00001" "DB00001" ...
  ..$ atc_codes              : tibble [5,656 × 10] (S3: tbl_df/tbl/data.frame)
  .. ..$ atc_code   : chr [1:5656] "B01AE02" "L01FE01" "R05CB13" "L01XX29" ...
  .. ..$ level_1    : chr [1:5656] "Direct thrombin inhibitors" "EGFR (Epidermal Growth Factor Receptor) inhibitors" "Mucolytics" "Other antineoplastic agents" ...
  .. ..$ code_1     : chr [1:5656] "B01AE" "L01FE" "R05CB" "L01XX" ...
  .. ..$ level_2    : chr [1:5656] "ANTITHROMBOTIC AGENTS" "MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES" "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS" "OTHER ANTINEOPLASTIC AGENTS" ...
  .. ..$ code_2     : chr [1:5656] "B01A" "L01F" "R05C" "L01X" ...
  .. ..$ level_3    : chr [1:5656] "ANTITHROMBOTIC AGENTS" "ANTINEOPLASTIC AGENTS" "COUGH AND COLD PREPARATIONS" "ANTINEOPLASTIC AGENTS" ...
  .. ..$ code_3     : chr [1:5656] "B01" "L01" "R05" "L01" ...
  .. ..$ level_4    : chr [1:5656] "BLOOD AND BLOOD FORMING ORGANS" "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" "RESPIRATORY SYSTEM" "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" ...
  .. ..$ code_4     : chr [1:5656] "B" "L" "R" "L" ...
  .. ..$ drugbank_id: chr [1:5656] "DB00001" "DB00002" "DB00003" "DB00004" ...
  ..$ patents                : tibble [12,214 × 6] (S3: tbl_df/tbl/data.frame)
  .. ..$ number             : chr [1:12214] "5180668" "1340417" "2184581" "2137237" ...
  .. ..$ country            : chr [1:12214] "United States" "Canada" "Canada" "Canada" ...
  .. ..$ approved           : chr [1:12214] "1993-01-19" "1999-03-02" "2005-02-22" "2004-10-26" ...
  .. ..$ expires            : chr [1:12214] "2010-01-19" "2016-03-02" "2015-02-28" "2013-05-28" ...
  .. ..$ pediatric_extension: chr [1:12214] "false" "false" "false" "false" ...
  .. ..$ drugbank_id        : chr [1:12214] "DB00001" "DB00002" "DB00003" "DB00003" ...
  ..$ drug_interactions      : tibble [2,855,848 × 4] (S3: tbl_df/tbl/data.frame)
  .. ..$ target_drugbank_id: chr [1:2855848] "DB06605" "DB06695" "DB01254" "DB01609" ...
  .. ..$ name              : chr [1:2855848] "Apixaban" "Dabigatran etexilate" "Dasatinib" "Deferasirox" ...
  .. ..$ description       : chr [1:2855848] "Apixaban may increase the anticoagulant activities of Lepirudin." "Dabigatran etexilate may increase the anticoagulant activities of Lepirudin." "The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin." "The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox." ...
  .. ..$ drugbank_id       : chr [1:2855848] "DB00001" "DB00001" "DB00001" "DB00001" ...
  ..$ sequences              : tibble [524 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ sequence   : chr [1:524] ">DB00001 sequence\nLTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\nEEYLQ" ">Cetuximab heavy chain\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\nTPFTSRLSINKDNSKSQVFFKMNSL"| __truncated__ ">Cetuximab light chain\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\nRFSGSGSGTDFTLSINSVESEDIAD"| __truncated__ ">Dornase alfa sequence\nLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP\nDTYHYVVSEPLGRNSYKERYLFVYR"| __truncated__ ...
  .. ..$ format     : chr [1:524] "FASTA" "FASTA" "FASTA" "FASTA" ...
  .. ..$ drugbank_id: chr [1:524] "DB00001" "DB00002" "DB00002" "DB00003" ...
  ..$ calculated_properties  : tibble [307,087 × 4] (S3: tbl_df/tbl/data.frame)
  .. ..$ kind       : chr [1:307087] "logP" "logS" "Water Solubility" "logP" ...
  .. ..$ value      : chr [1:307087] "-0.76" "-4.7" "4.64e-02 g/l" "-14" ...
  .. ..$ source     : chr [1:307087] "ALOGPS" "ALOGPS" "ALOGPS" "ChemAxon" ...
  .. ..$ drugbank_id: chr [1:307087] "DB00006" "DB00006" "DB00006" "DB00006" ...
  ..$ experimental_properties: tibble [7,190 × 4] (S3: tbl_df/tbl/data.frame)
  .. ..$ kind       : chr [1:7190] "Water Solubility" "Melting Point" "Isoelectric Point" "Molecular Weight" ...
  .. ..$ value      : chr [1:7190] "Soluble" "65 °C" "3.7" "6979.0" ...
  .. ..$ source     : chr [1:7190] "Health Canada drug label" "Otto, A. & Seckler, R. Eur. J. Biochem. 202:67-73 (1991)" "Health Canada drug label" "" ...
  .. ..$ drugbank_id: chr [1:7190] "DB00001" "DB00001" "DB00001" "DB00001" ...
  ..$ external_identifiers   : tibble [89,758 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ resource   : chr [1:89758] "Drugs Product Database (DPD)" "PubChem Substance" "KEGG Drug" "PharmGKB" ...
  .. ..$ identifier : chr [1:89758] "11916" "46507011" "D06880" "PA450195" ...
  .. ..$ drugbank_id: chr [1:89758] "DB00001" "DB00001" "DB00001" "DB00001" ...
  ..$ pathway                :List of 3
  .. ..$ general_information: tibble [3,780 × 4] (S3: tbl_df/tbl/data.frame)
  .. .. ..$ smpdb_id   : chr [1:3780] "SMP0000278" "SMP0000474" "SMP0000277" "SMP0000280" ...
  .. .. ..$ name       : chr [1:3780] "Lepirudin Action Pathway" "Cetuximab Action Pathway" "Bivalirudin Action Pathway" "Alteplase Action Pathway" ...
  .. .. ..$ category   : chr [1:3780] "drug_action" "drug_action" "drug_action" "drug_action" ...
  .. .. ..$ drugbank_id: chr [1:3780] "DB00001" "DB00002" "DB00006" "DB00009" ...
  .. ..$ pathway_drugs      : tibble [7,438 × 3] (S3: tbl_df/tbl/data.frame)
  .. .. ..$ drugbank_id: chr [1:7438] "DB00001" "DB01022" "DB01373" "DB00002" ...
  .. .. ..$ name       : chr [1:7438] "Lepirudin" "Phylloquinone" "Calcium" "Cetuximab" ...
  .. .. ..$ smpdb_id   : chr [1:7438] "SMP0000278" "SMP0000278" "SMP0000278" "SMP0000474" ...
  .. ..$ pathway_enzyme     : tibble [15,198 × 2] (S3: tbl_df/tbl/data.frame)
  .. .. ..$ enzyme  : chr [1:15198] "P00734" "P00748" "P02452" "P03952" ...
  .. .. ..$ smpdb_id: chr [1:15198] "SMP0000278" "SMP0000278" "SMP0000278" "SMP0000278" ...
  ..$ reactions              :List of 2
  .. ..$ general_information: tibble [4,046 × 6] (S3: tbl_df/tbl/data.frame)
  .. .. ..$ sequence           : chr [1:4046] "1" "2" "3" "4" ...
  .. .. ..$ left_drugbank_id   : chr [1:4046] "DB00001" "DBMET03462" "DBMET03463" "DBMET03464" ...
  .. .. ..$ left_drugbank_name : chr [1:4046] "Lepirudin" "M1 (1-64)" "M2 (1-63)" "M3 (1-62)" ...
  .. .. ..$ right_drugbank_id  : chr [1:4046] "DBMET03462" "DBMET03463" "DBMET03464" "DBMET03465" ...
  .. .. ..$ right_drugbank_name: chr [1:4046] "M1 (1-64)" "M2 (1-63)" "M3 (1-62)" "M4 (1-61)" ...
  .. .. ..$ drugbank_id        : chr [1:4046] "DB00001" "DB00001" "DB00001" "DB00001" ...
  .. ..$ reactions_enzymes  : tibble [3,737 × 3] (S3: tbl_df/tbl/data.frame)
  .. .. ..$ enzyme_id : chr [1:3737] "BE0002638" "BE0002362" "BE0002638" "BE0002362" ...
  .. .. ..$ name      : chr [1:3737] "Cytochrome P450 3A4" "Cytochrome P450 3A5" "Cytochrome P450 3A4" "Cytochrome P450 3A5" ...
  .. .. ..$ uniprot_id: chr [1:3737] "P08684" "P20815" "P08684" "P20815" ...
  ..$ snp_effects            : tibble [211 × 9] (S3: tbl_df/tbl/data.frame)
  .. ..$ protein_name   : chr [1:211] "Low affinity immunoglobulin gamma Fc region receptor II-a" "Low affinity immunoglobulin gamma Fc region receptor III-A" "Interferon lambda-3" "Interferon lambda-3" ...
  .. ..$ gene_symbol    : chr [1:211] "FCGR2A" "FCGR3A" "IFNL3" "IFNL3" ...
  .. ..$ uniprot_id     : chr [1:211] "P12318" "P08637" "Q8IZI9" "Q8IZI9" ...
  .. ..$ rs_id          : chr [1:211] "rs1801274" "rs396991" "rs12979860" "rs12979860" ...
  .. ..$ allele         : chr [1:211] "" "" "" "" ...
  .. ..$ defining_change: chr [1:211] "H allelle" "G > T" "C > T" "C > T" ...
  .. ..$ description    : chr [1:211] "Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer." "Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer." "Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peg"| __truncated__ "Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peg"| __truncated__ ...
  .. ..$ pubmed_id      : chr [1:211] "17704420" "17704420" "24096968" "24096968" ...
  .. ..$ drugbank_id    : chr [1:211] "DB00002" "DB00002" "DB00008" "DB00022" ...
  ..$ snp_adverse_reactions  : tibble [113 × 9] (S3: tbl_df/tbl/data.frame)
  .. ..$ protein_name    : chr [1:113] "Receptor tyrosine-protein kinase erbB-2" "Cytochrome P450 1A2" "Glutamate receptor ionotropic, kainate 2" "Glutamate receptor 3" ...
  .. ..$ gene_symbol     : chr [1:113] "ERBB2" "CYP1A2" "GRIK2" "GRIA3" ...
  .. ..$ uniprot_id      : chr [1:113] "P04626" "P05177" "Q13002" "P42263" ...
  .. ..$ rs_id           : chr [1:113] "rs1136201" "rs762551" "rs2518224" "rs4825476" ...
  .. ..$ allele          : chr [1:113] "" "" "" "" ...
  .. ..$ adverse_reaction: chr [1:113] "G Allele, heterozygote" "C allele" "C Allele, homozygote" "G allele" ...
  .. ..$ description     : chr [1:113] "Patients with this genotype have increased risk of cardiotoxicity with trastuzumab." "Patients with this genotype have increased risk of a non-fatal myocardial infarction with caffeine" "Patients with this genotype have increased frequency of suicidal ideation with citalopram" "Patients with this genotype have increased frequency of suicidal ideation with citalopram" ...
  .. ..$ pubmed_id       : chr [1:113] "17693647" "16522833" "17898344" "17898344" ...
  .. ..$ drugbank_id     : chr [1:113] "DB00072" "DB00201" "DB00215" "DB00215" ...
  ..$ food_interactions      : tibble [2,512 × 2] (S3: tbl_df/tbl/data.frame)
  .. ..$ food_interaction: chr [1:2512] "Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginge"| __truncated__ "Avoid echinacea." "Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry"| __truncated__ "Drink plenty of fluids." ...
  .. ..$ drugbank_id     : chr [1:2512] "DB00001" "DB00006" "DB00006" "DB00008" ...
  ..$ pdb_entries            : tibble [303,926 × 2] (S3: tbl_df/tbl/data.frame)
  .. ..$ pdb_entry  : chr [1:303926] "1a3g" "1a50" "1a5a" "1a5b" ...
  .. ..$ drugbank_id: chr [1:303926] "DB00114" "DB00114" "DB00114" "DB00114" ...
  ..$ ahfs_codes             : tibble [0 × 0] (S3: tbl_df/tbl/data.frame)
 Named list()
  ..$ affected_organisms     : tibble [3,453 × 2] (S3: tbl_df/tbl/data.frame)
  .. ..$ affected_organism: chr [1:3453] "Humans and other mammals" "Humans and other mammals" "Humans and other mammals" "Humans and other mammals" ...
  .. ..$ drugbank_id      : chr [1:3453] "DB00001" "DB00002" "DB00003" "DB00004" ...
  ..$ groups                 : tibble [20,354 × 2] (S3: tbl_df/tbl/data.frame)
  .. ..$ group      : chr [1:20354] "approved" "withdrawn" "approved" "approved" ...
  .. ..$ drugbank_id: chr [1:20354] "DB00001" "DB00001" "DB00002" "DB00003" ...
  ..$ external_links         : tibble [3,088 × 3] (S3: tbl_df/tbl/data.frame)
  .. ..$ resource   : chr [1:3088] "RxList" "Drugs.com" "RxList" "Drugs.com" ...
  .. ..$ url        : chr [1:3088] "http://www.rxlist.com/cgi/generic/lepirudin.htm" "http://www.drugs.com/cdi/lepirudin.html" "http://www.rxlist.com/cgi/generic3/erbitux.htm" "http://www.drugs.com/cdi/cetuximab.html" ...
  .. ..$ drugbank_id: chr [1:3088] "DB00001" "DB00001" "DB00002" "DB00002" ...
 $ salts     : tibble [2,922 × 8] (S3: tbl_df/tbl/data.frame)
  ..$ db_salt_id       : chr [1:2922] "DBSALT000105" "DBSALT003182" "DBSALT001439" "DBSALT000093" ...
  ..$ name             : chr [1:2922] "Leuprolide acetate" "Leuprolide mesylate" "Sermorelin acetate" "Goserelin acetate" ...
  ..$ unii             : chr [1:2922] "37JNS02E7V" "8E3C3C493W" "00IBG87IQW" "6YUU2PV0U8" ...
  ..$ cas_number       : chr [1:2922] "74381-53-6" "944347-41-5" "114466-38-5" "145781-92-6" ...
  ..$ inchikey         : chr [1:2922] "YFDMUNOZURYOCP-XNHQSDQCSA-N" "MBIDSOMXPLCOHS-XNHQSDQCSA-N" "" "IKDXDQDKCZPQSZ-JHYYTBFNSA-N" ...
  ..$ average_mass     : chr [1:2922] "1269.473" "1305.52" NA "1329.4624" ...
  ..$ monoisotopic_mass: chr [1:2922] "1268.666591578" "1304.633577372" NA "1328.662568858" ...
  ..$ drugbank_id      : chr [1:2922] "DB00007" "DB00007" "DB00010" "DB00014" ...
 $ products  : tibble [455,970 × 19] (S3: tbl_df/tbl/data.frame)
  ..$ name                  : chr [1:455970] "Refludan" "Refludan" "Refludan" "Refludan" ...
  ..$ labeller              : chr [1:455970] "Bayer Ag" "Bayer Ag" "Celgene Corporation" "Celgene Corporation" ...
  ..$ ndc_id                : chr [1:455970] "" "" "" "" ...
  ..$ ndc_product_code      : chr [1:455970] "50419-150" "" "" "" ...
  ..$ dpd_id                : chr [1:455970] "" "02240996" "" "" ...
  ..$ ema_product_code      : chr [1:455970] "" "" "EMEA/H/C/000122" "EMEA/H/C/000122" ...
  ..$ ema_ma_number         : chr [1:455970] "" "" "EU/1/97/035/001" "EU/1/97/035/002" ...
  ..$ started_marketing_on  : chr [1:455970] "1998-03-06" "2000-01-31" "2016-09-08" "2016-09-08" ...
  ..$ ended_marketing_on    : chr [1:455970] "2013-06-30" "2013-07-26" "2012-04-24" "2012-04-24" ...
  ..$ dosage_form           : chr [1:455970] "Powder" "Powder, for solution" "Injection, solution, concentrate" "Injection, solution, concentrate" ...
  ..$ strength              : chr [1:455970] "50 mg/1mL" "50 mg / vial" "50 mg" "50 mg" ...
  ..$ route                 : chr [1:455970] "Intravenous" "Intravenous" "Intravenous" "Intravenous" ...
  ..$ fda_application_number: chr [1:455970] "NDA020807" "" "" "" ...
  ..$ generic               : chr [1:455970] "false" "false" "false" "false" ...
  ..$ over_the_counter      : chr [1:455970] "false" "false" "false" "false" ...
  ..$ approved              : chr [1:455970] "true" "true" "false" "false" ...
  ..$ country               : chr [1:455970] "US" "Canada" "EU" "EU" ...
  ..$ source                : chr [1:455970] "FDA NDC" "DPD" "EMA" "EMA" ...
  ..$ drugbank_id           : chr [1:455970] "DB00001" "DB00001" "DB00001" "DB00001" ...